Lannett Co Inc Revenue 2006-2019 | LCI

Lannett Co Inc revenue from 2006 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Lannett Co Inc Annual Revenue
(Millions of US $)
2019 $655
2018 $685
2017 $633
2016 $542
2015 $407
2014 $274
2013 $151
2012 $123
2011 $107
2010 $125
2009 $119
2008 $72
2007 $83
2006 $64
2005 $45
Lannett Co Inc Quarterly Revenue
(Millions of US $)
Q4 2019 $134
Q3 2019 $173
Q2 2018 $194
Q1 2018 $155
Q4 2018 $171
Q3 2018 $174
Q2 2017 $184
Q1 2017 $155
Q4 2017 $139
Q3 2017 $162
Q2 2016 $171
Q1 2016 $162
Q4 2016 $169
Q3 2016 $140
Q2 2015 $127
Q1 2015 $106
Q4 2015 $99
Q3 2015 $99
Q2 2014 $115
Q1 2014 $93
Q4 2014 $81
Q3 2014 $80
Q2 2013 $67
Q1 2013 $46
Q4 2013 $40
Q3 2013 $39
Q2 2012 $37
Q1 2012 $35
Q4 2012 $36
Q3 2012 $31
Q2 2011 $28
Q1 2011 $29
Q4 2011 $26
Q3 2011 $26
Q2 2010 $30
Q1 2010 $25
Q4 2010 $34
Q3 2010 $31
Q2 2009 $29
Q1 2009 $31
Q4 2009 $35
Q3 2009 $29
Q2 2008 $29
Q1 2008 $26
Q4 2008 $21
Q3 2008 $17
Q2 2007 $18
Q1 2007 $18
Q4 2007 $17
Q3 2007 $20
Q2 2006 $23
Q1 2006 $22
Q4 2006 $19
Q3 2006 $16
Q2 2005 $15
Q1 2005 $14
Q4 2005 $9
Q3 2005 $8
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.483B $0.655B
Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous products across a wide range of therapeutic areas. Lannett believes that their ability to select viable products for development, efficiently develop such products, including obtaining any applicable regulatory approvals, vertically integrate themselves into certain specialty markets and achieve economies in production are all critical for their success in the generic pharmaceutical industry in which they operate. Lannett Company, Inc., continues to dedicate significant capital toward developing new products as they believe their success is linked to their ability to continually introduce new generic products into the marketplace.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $61.352B 37.78
Takeda Pharmaceutical (TAK) Japan $54.643B 8.55
Astellas Pharma (ALPMY) Japan $31.383B 14.95
Merck (MKGAF) Germany $14.986B 20.45
Eisai (ESALY) Japan $14.663B 22.44
UCB SA (UCBJF) Belgium $14.373B 0.00
Grifols, S.A (GRFS) Spain $14.219B 18.14
Ono Pharmaceutical (OPHLF) Japan $9.212B 19.69
IPSEN SA ADR (IPSEY) France $9.033B 0.00
Neurocrine Biosciences (NBIX) United States $8.869B 0.00
Ionis Pharmaceuticals (IONS) United States $7.944B 17.13
Sage Therapeutics (SAGE) United States $7.481B 0.00
Catalent (CTLT) United States $7.273B 28.75
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $7.257B 0.00
Jazz Pharmaceuticals (JAZZ) Ireland $6.859B 9.03
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.094B 0.00
STADA ARZNEIMI (STDAF) Germany $5.547B 0.00
Orion OYJ (ORINY) Finland $5.271B 27.14
Hypermarcas (HYPMY) Brazil $5.262B 18.91
United Therapeutics (UTHR) United States $3.581B 0.00
FibroGen (FGEN) United States $3.521B 88.07
Arrowhead Pharmaceuticals (ARWR) United States $3.470B 79.57
Evotec AG (EVTCY) Germany $3.277B 44.87
Nektar Therapeutics (NKTR) United States $3.115B 0.00
Taro Pharmaceutical Industries (TARO) Israel $2.930B 10.50
PTC Therapeutics (PTCT) United States $2.265B 0.00
Tilray (TLRY) Canada $2.196B 0.00
Xencor (XNCR) United States $2.068B 45.09
Zogenix (ZGNX) United States $1.974B 0.00
Portola Pharmaceuticals (PTLA) United States $1.910B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.620B 58.97
Corcept Therapeutics (CORT) United States $1.613B 22.17
USANA Health Sciences (USNA) United States $1.569B 15.74
Heron Therapeutics (HRTX) United States $1.485B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.418B 0.00
CLINIGEN GP (CLIGF) United Kingdom $1.308B 0.00
Radius Health (RDUS) United States $1.273B 0.00
Enanta Pharmaceuticals (ENTA) United States $1.197B 19.75
ArQule (ARQL) United States $1.120B 0.00
Endo (ENDP) Ireland $1.093B 1.92
Aerie Pharmaceuticals (AERI) United States $0.976B 0.00
Theravance Biopharma (TBPH) Cayman Islands $0.973B 0.00
Spectrum Pharmaceuticals (SPPI) United States $0.924B 0.00
TherapeuticsMD (TXMD) United States $0.902B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $0.900B 4.01
Dova Pharmaceuticals (DOVA) United States $0.808B 0.00
Organogenesis Holdings (ORGO) United States $0.716B 0.00
Karyopharm Therapeutics (KPTI) United States $0.672B 0.00
Concordia (CXRXF) Canada $0.588B 0.00
Flexion Therapeutics (FLXN) United States $0.550B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.546B 0.00
Akebia Therapeutics (AKBA) United States $0.511B 0.00
Indivior (INVVY) United States $0.495B 1.79
ChemoCentryx (CCXI) United States $0.464B 0.00
Aptorum Group (APM) Hong Kong, SAR China $0.462B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $0.452B 0.00
Siga Technologies (SIGA) United States $0.450B 1.05
Translate Bio (TBIO) United States $0.447B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.404B 0.00
Collegium Pharmaceutical (COLL) United States $0.404B 0.00
DURECT (DRRX) United States $0.376B 0.00
ImmunoGen (IMGN) United States $0.373B 0.00
Innate Pharma SA (IPHYF) France $0.370B 0.00
BioSpecifics Technologies Corp (BSTC) United States $0.362B 16.45
Harpoon Therapeutics (HARP) United States $0.332B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.319B 0.00
Dermira (DERM) United States $0.310B 0.00
OptiNose (OPTN) United States $0.302B 0.00
Ardelyx (ARDX) United States $0.291B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.276B 0.00
Molecular Templates (MTEM) United States $0.273B 0.00
Recro Pharma (REPH) United States $0.272B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.268B 0.00
Xeris Pharmaceuticals (XERS) United States $0.243B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.236B 0.00
KalVista Pharmaceuticals (KALV) United States $0.215B 0.00
CV Sciences (CVSI) United States $0.209B 0.00
GlycoMimetics (GLYC) United States $0.204B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.199B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.198B 0.00
CannTrust Holdings (CTST) Canada $0.194B 0.00
Nature's Sunshine Products (NATR) United States $0.180B 30.07
AcelRx Pharmaceuticals (ACRX) United States $0.176B 0.00
Ocular Therapeutix (OCUL) United States $0.164B 0.00
Taiwan Liposome (TLC) Taiwan $0.159B 0.00
Concert Pharmaceuticals (CNCE) United States $0.155B 0.00
Calithera Biosciences (CALA) United States $0.146B 0.00
IMV INC (IMV) Canada $0.139B 0.00
Redhill Biopharma (RDHL) Israel $0.135B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.133B 0.00
MEI Pharma (MEIP) United States $0.128B 0.00
Generex Biotechnology (GNBT) United States $0.127B 0.00
Jounce Therapeutics (JNCE) United States $0.115B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.112B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Cardiome Pharma (CORV) Canada $0.101B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.083B 0.00
Aquestive Therapeutics (AQST) United States $0.083B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.081B 31.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.081B 0.00
Majesco Entertainment (PTE) United States $0.079B 0.00
Lipocine (LPCN) United States $0.078B 0.00
Entasis Therapeutics Holdings (ETTX) United States $0.076B 0.00
MediWound (MDWD) Israel $0.074B 0.00
Champions Oncology (CSBR) United States $0.073B 0.00
Neos Therapeutics (NEOS) United States $0.071B 0.00
Genocea Biosciences (GNCA) United States $0.069B 0.00
Aclaris Therapeutics (ACRS) United States $0.069B 0.00
Otonomy (OTIC) United States $0.069B 0.00
Natural Alternatives (NAII) United States $0.066B 9.95
Infinity Pharmaceuticals (INFI) United States $0.066B 0.00
IntelGenx Technologies (IGXT) Canada $0.064B 0.00
SCYNEXIS (SCYX) United States $0.064B 0.00
Novan (NOVN) United States $0.062B 0.00
Melinta Therapeutics (MLNT) United States $0.060B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.059B 0.00
ElectroCore (ECOR) United States $0.058B 0.00
Iterum Therapeutics (ITRM) Ireland $0.055B 0.00
Pharmaxis (PXSLY) Australia $0.055B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.052B 0.00
Nivalis Therapeutics (ALPN) United States $0.050B 0.00
Capnia (SLNO) United States $0.049B 0.00
CTI BioPharma (CTIC) United States $0.046B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.043B 0.00
Mannatechorporated (MTEX) United States $0.041B 0.00
Mast Therapeutics (SVRA) United States $0.038B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.037B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.035B 0.00
Jaguar Animal Health (JAGX) United States $0.034B 0.00
Biomerica (BMRA) United States $0.031B 0.00
Opexa Therapeutics (ACER) United States $0.031B 0.00
Bio-Path Holdings (BPTH) United States $0.031B 0.00
China SXT Pharmaceuticals (SXTC) China $0.031B 0.00
PharmAthene (ALT) United States $0.031B 0.00
ProPhase Labs (PRPH) United States $0.022B 0.00
Cyanotech (CYAN) United States $0.015B 0.00
Regulus Therapeutics (RGLS) United States $0.015B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.014B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.014B 0.00
Vical (BBI) United States $0.013B 0.00
Heat Biologics (HTBX) United States $0.013B 0.00
Achieve Life Sciences (ACHV) United States $0.012B 0.00
HANCOCK JAFFE (HJLI) United States $0.012B 0.00
Shineco (TYHT) China $0.012B 17.33
Eyegate Pharmaceuticals (EYEG) United States $0.010B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.006B 0.00
VAXART, INC (VXRT) United States $0.006B 0.00
Onconova Therapeutics (ONTX) United States $0.006B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
Flex Pharma (SLRX) United States $0.004B 0.00
Midatech Pharma (MTP) United Kingdom $0.004B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.001B 0.00
Advanced Accelerator Applications S.A (AAAP) France $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00